Which weight for weight-based dosage regimens in obese patients?

被引：23

作者：

Erstad, BL ^{[1
]}

机构：

[1] Coll Pharm, Dept Pharm Practice & Sci, Tucson, AZ 85721 USA

来源：

AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY | 2002年 / 59卷 / 21期

关键词：

D O I：

10.1093/ajhp/59.21.2105

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：2105 / 2110

页数：6

共 32 条

[1] PHENYTOIN DISPOSITION IN OBESITY - DETERMINATION OF LOADING DOSE [J].

ABERNETHY, DR ;

GREENBLATT, DJ .

ARCHIVES OF NEUROLOGY, 1985, 42 (05) :468-471

[2] DIGOXIN DISPOSITION IN OBESITY - CLINICAL PHARMACOKINETIC INVESTIGATION [J].

ABERNETHY, DR ;

GREENBLATT, DJ ;

SMITH, TW .

AMERICAN HEART JOURNAL, 1981, 102 (04) :740-744

[3]

[Anonymous], 1976, RES OBESITY

[4]

[Anonymous], 1998, NIH PUBL

[5] AMIKACIN PHARMACOKINETICS IN MORBIDLY OBESE PATIENTS [J].

BAUER, LA ;

BLOUIN, RA ;

GRIFFEN, WO ;

RECORD, KE ;

BELL, RM .

AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1980, 37 (04) :519-522

[6] INFLUENCE OF WEIGHT ON AMINOGLYCOSIDE PHARMACOKINETICS IN NORMAL WEIGHT AND MORBIDLY OBESE PATIENTS [J].

BAUER, LA ;

EDWARDS, WAD ;

DELLINGER, EP ;

SIMONOWITZ, DA .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1983, 24 (05) :643-647

[7]

BICKEL MH, 1994, ADV DRUG RES, V25, P56

[8] TOBRAMYCIN PHARMACOKINETICS IN MORBIDLY OBESE PATIENTS [J].

BLOUIN, RA ;

MANN, HJ ;

GRIFFEN, WO ;

BAUER, LA ;

RECORD, KE .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1979, 26 (04) :508-512

[9] Pharmacokinetic considerations in obesity [J].

Blouin, RA ;

Warren, GW .

JOURNAL OF PHARMACEUTICAL SCIENCES, 1999, 88 (01) :1-7

[10] SIGNIFICANT WEIGHT-REDUCTION IN OBESE SUBJECTS ENHANCES CARBAMAZEPINE ELIMINATION [J].

CARACO, Y ;

ZYLBERKATZ, E ;

BERRY, EM ;

LEVY, M .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (05) :501-506

← 1 2 3 4 →